TOP TIERMARKET NEWSWIRE
Movers explained · September 19, 2026

Why Is ARCTURUS THERAPEUTIC (ARCT) Stock Moving Today?

By the Top Tier Newswire AI Desk · reviewed against 1 wire stories

ARCTURUS THERAPEUTIC (ARCT) is drawing unusual attention today. Our newswire has captured 1 story on ARCT across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 67/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

The written analysis for ARCT publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.

ARCT by the numbers

Coverage: 1 stories / 1 sourcesAI sentiment: 67/100 (bullish)
AI sentiment, last 36h · averaged over 1 story · 67/100 bullish
AI sentiment 67/100 (bullish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 1 story on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agonowStockTitan · sentiment 67 · Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics PlatformStockTitan · 67Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clin…
1d agoStockTitanBULLISH 67Product/PR

Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform

About 10,000 people in Europe and the U.S. have OTC deficiency; ARCT-810 has FDA and EMA designations before Arcturus’ Sept. 23 presentation.

Frequently asked questions

Why is ARCT stock moving today?

ARCTURUS THERAPEUTIC (ARCT) is drawing unusual attention today. Our newswire has captured 1 story on ARCT across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 67/100). The most recent driver: "Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform" (StockTitan).

Is ARCT a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of ARCT coverage reads 67/100 over 1 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.

More moves explained today

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on ARCT: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.